This startup specializes in drug discovery by developing botanical medicines and therapeutics from natural compounds, utilizing cannabis molecular analysis and pre-clinical trials. It enables researchers to evaluate the efficacy of cannabis and psilocybin extracts on various cell line models, facilitating the integration of botanical medicine into the pharmaceutical industry.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The pharmaceutical industry faces challenges in developing therapeutics from botanical sources due to the complexity of natural compounds and the need for rigorous scientific validation. Traditional drug discovery methods may not be well-suited for identifying and isolating active molecules from complex botanical extracts like cannabis and psilocybin mushrooms.
Solution
Cannasoul is a drug discovery company focused on developing therapeutics derived from natural compounds, including those from cannabis and psilocybin mushrooms. The company utilizes a proprietary analytical platform, data-driven approach, and clinical trial framework to support active compound identification and development, from botanical extract to clinically approved formulation. Cannasoul's services include analytical development, IP licensing, and pre-clinical and clinical trials. The company's bioanalytical services support preclinical and clinical studies, including analytical method development and validation for both active pharmaceutical ingredients (APIs) and pharmaceuticals. Cannasoul also offers extraction, separation, and isolation technologies for extracting specific compounds from botanical matrices, including the isolation of rare or minute compounds for structural determination and the creation of analytical standards.
Target Audience
Cannasoul serves pharmaceutical companies, researchers, and cultivators seeking to develop and validate botanical-based therapeutics.
Features
- Analytical services using HPLC, UPLC, LC-MS/MS (Orbitrap), LC-MS/MS (QQQ), GC-MS/MS (QQQ), and ICP-MS
- Bioanalytical services using high-resolution Orbitrap LC-MS/MS to detect molecules down to the ppb level
- Extraction, isolation, and compound discovery services for botanical matrices
- Pre-clinical and clinical study support with bioanalysis of samples
- Cannabis-related services including batch release testing under IMC-GMP and IEC/ISO 17025, terpenes and flavonoids analysis, and full cannabinoid mapping
- Development of cell-based disease models to understand biological effects of cannabis strains
- High-throughput screening technology for plant active compounds
- Data collection and bioinformatics for plant materials screened and their biological effects